May & Baker Nigeria Past Earnings Performance
Past criteria checks 2/6
May & Baker Nigeria has been growing earnings at an average annual rate of 22%, while the Pharmaceuticals industry saw earnings growing at 6.4% annually. Revenues have been growing at an average rate of 19.1% per year. May & Baker Nigeria's return on equity is 12.3%, and it has net margins of 5.5%.
Key information
22.0%
Earnings growth rate
18.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 21.6% |
| Revenue growth rate | 19.1% |
| Return on equity | 12.3% |
| Net Margin | 5.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How May & Baker Nigeria makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19,695 | 1,083 | 5,127 | 0 |
| 30 Sep 23 | 18,283 | 772 | 3,646 | 0 |
| 30 Jun 23 | 16,339 | 1,682 | 3,496 | 0 |
| 31 Mar 23 | 15,237 | 1,580 | 3,224 | 0 |
| 31 Dec 22 | 14,328 | 1,491 | 3,219 | 0 |
| 30 Sep 22 | 14,184 | 1,597 | 3,204 | 0 |
| 30 Jun 22 | 13,150 | 987 | 2,960 | 0 |
| 31 Mar 22 | 12,538 | 997 | 2,972 | 0 |
| 31 Dec 21 | 11,902 | 1,050 | 2,906 | 0 |
| 30 Sep 21 | 11,016 | 1,165 | 2,860 | 0 |
| 30 Jun 21 | 10,843 | 1,081 | 2,848 | 0 |
| 31 Mar 21 | 10,264 | 1,169 | 2,642 | 0 |
| 31 Dec 20 | 9,390 | 965 | 2,344 | 0 |
| 30 Sep 20 | 8,604 | 924 | 2,129 | 0 |
| 30 Jun 20 | 8,097 | 869 | 1,959 | 0 |
| 31 Mar 20 | 8,041 | 625 | 1,922 | 0 |
| 31 Dec 19 | 8,080 | 716 | 1,950 | 0 |
| 30 Sep 19 | 7,926 | 402 | 1,960 | 0 |
| 30 Jun 19 | 7,999 | 365 | 2,028 | 0 |
| 31 Mar 19 | 8,239 | 314 | 2,102 | 0 |
| 31 Dec 18 | 8,552 | 343 | 2,093 | 0 |
| 30 Sep 18 | 7,672 | 823 | 1,856 | 0 |
| 30 Jun 18 | 8,200 | 796 | 1,776 | 0 |
| 31 Mar 18 | 7,877 | 764 | 1,665 | 0 |
| 31 Dec 17 | 8,057 | 626 | 1,737 | 0 |
| 30 Sep 17 | 9,451 | 133 | 1,926 | 0 |
| 30 Jun 17 | 9,232 | 24 | 1,843 | 0 |
| 31 Mar 17 | 9,007 | -42 | 1,835 | 0 |
| 31 Dec 16 | 8,469 | -41 | 1,762 | 0 |
| 30 Sep 16 | 8,229 | 71 | 1,807 | 0 |
| 30 Jun 16 | 7,863 | 68 | 1,839 | 0 |
| 31 Mar 16 | 7,872 | 135 | 1,901 | 0 |
| 31 Dec 15 | 7,568 | 68 | 1,866 | 0 |
| 30 Sep 15 | 7,450 | 198 | 1,902 | 0 |
| 30 Jun 15 | 7,348 | 254 | 1,916 | 0 |
| 31 Mar 15 | 7,153 | 108 | 1,840 | 0 |
| 31 Dec 14 | 7,019 | 63 | 1,892 | 0 |
| 30 Sep 14 | 6,605 | -163 | 2,202 | 0 |
| 30 Jun 14 | 6,584 | -299 | 2,665 | 0 |
| 31 Mar 14 | 6,323 | -207 | 2,238 | 0 |
| 31 Dec 13 | 6,368 | -103 | 1,842 | 0 |
| 30 Sep 13 | 6,398 | -1 | 2,770 | 0 |
| 30 Jun 13 | 6,106 | 84 | 1,849 | 0 |
Quality Earnings: MAYBAKER has high quality earnings.
Growing Profit Margin: MAYBAKER's current net profit margins (5.5%) are lower than last year (10.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAYBAKER's earnings have grown significantly by 22% per year over the past 5 years.
Accelerating Growth: MAYBAKER's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MAYBAKER had negative earnings growth (-27.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.4%).
Return on Equity
High ROE: MAYBAKER's Return on Equity (12.3%) is considered low.